IL-36 as a new biomarker/tx target in SpA? Check out this interesting in vitro study out of the UK and the IL-36 upstream induction of the IL-17/IL-23 pathway. #EULAR2020 @RheumNow #SAT0356 https://t.co/YTVepexd45

• EULAR Abstract Archive

Spanish COSPAR registry results reveal changes in axSpA pt gut microbiota which are associated with radiographic damage, disease activity, affectation of enthesis and axial mobility. #SAT0362 https://t.co/goo4Qkaqdb #EULAR2020 @RheumNow

• EULAR Abstract Archive

10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3

• EULAR Abstract Archive

In regard to biosimilars, what has your experience been? #EULAR2020 @RheumNow

What do you think of #EULAR2020goesvirtual compared to an in person #EULAR? @eular_org @RheumNow @CRASCRRheum #EULAR2020goesvirtual

Another study shows that US guided SIJs in axSpA pts are safe and effective. Abstract #AB0642. #EULAR2020 @RheumNow https://t.co/KMPioCKr0n

• EULAR Abstract Archive

“Let’s consider treating nr-ax SpA and axSpA as serious, similar entities for better treatment options for our patients.” Dr. D. Poddubnyy discussing EXCEED study results and extrapolation of data. #EULAR2020 @RheumNow

Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI

• https://twitter.com/pkiely500/status/1268871993539072001

#eular2020 #op0226 humanized antiIL17a ab NETAKIMAB (NTK)for PsA Ph3 PATERA trial: pts who failed cDMARDs and/or 1TNFi experience significantly ⬆️ ACR20/50/70 &PsACR response vs PBO. DAPSA remission 36.08% NTK vs 13.4%PBO. AEs: lympho&neutropenia, ⬆️cholesterol,⬆️bili @RheumNow https://t.co/xqc9Z1T9O0

I have been impressed with the quality and content of the presentations at #EULAR2020! Here I am trying to navigate the meeting in between telehealth visits at my command center! @RheumNow https://t.co/aGDAr8PPkA

Big one from plenary, new option in ANCA-associated vasculitis: avacopan (anti-C5a) vs prednisolone in patients receiving CYC/RTX: non-inf at 26w, superior at 52w in the phase III ADVOCATE trial with reduction in steroid toxicity Merkel, Jayne et al OP0011 #EULAR2020 @RheumNow

#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h

You might think that steroid exposure in PMR patients wouldn't lead to new comorbidities. These data beg to differ. New steroid-related comorbidities ++ across domains vs matched controls in real-world US claims data. We need steroid-sparing in PMR. OP0271 #EULAR2020 @RheumNow https://t.co/mSzWcJSpfV

New #therapeutic strategies in #SLE management #EULAR2020 https://t.co/dhvTKd4EGB

Does TCZ actually fix GCA? @nihrheumatology cohort w serial PET/CT q6m: FDG uptake (PETVAS) reduces longitudinally over 2y but does not normalise, w rebound on TCZ cessation Ongoing reductions in year 2? GCA doesn't sleep. @KQuinnRheum @petercgrayson OP0144 #EULAR2020 @RheumNow https://t.co/aczQbONcNc